CAR-T & Cell Therapy in China
China has developed significant CAR-T cell therapy infrastructure, with multiple approved products and active clinical programmes at specialist haematology centres. For international patients facing relapsed or refractory blood cancers, a structured expert case review can help clarify whether CAR-T may be a relevant option, what eligibility assessment involves, and how coordination with Chinese centres works in practice.
Quick Answer
CAR-T cell therapy is available in China for relapsed or refractory lymphoma, multiple myeloma, and select solid tumours. China has approved multiple CAR-T products and has clinical experience in internationally published studies. International patients can request remote MDT case review to assess eligibility before travelling.
Key Topics Covered
Articles & Guides
What Is CT041 (Satri-Cel)? World's First Approved CAR-T for Solid Tumours
CAR-T Therapy Process and Timeline for International Patients in China
CAR-T Therapy in China: What Foreign Patients Should Know
CAR-T Therapy for Lymphoma: Who Is Eligible and What to Expect
CAR-T Therapy for Multiple Myeloma: Who Is Eligible and What to Expect
How Much Does CAR-T Cost in China for International Patients?
Side Effects of CAR-T Therapy: What Patients Should Know
CAR-T vs Targeted Therapy: What's the Difference and How Do You Decide?
CAR-T vs Chemotherapy: What's the Difference and How Do You Decide?
CAR-T vs Bone Marrow Transplant: How Do Families Decide?
How to Decide Between CAR-T and Other Cancer Therapy After Relapse
What to Expect When Considering CAR-T Therapy and Modern Cancer Treatment Options
CAR-T Cell Therapy for Solid Tumours: CT041 and the Claudin18.2 Breakthrough
What Should Patients Know About CAR-T Therapy for Solid Tumors?
Blood Cancer Treatments Beyond Chemotherapy and CAR-T
Gastric Cancer Treatment in China: Targeted Therapy, Immunotherapy, and the Coming World-First Solid Tumour CAR-T
Related Services & Areas
CAR-T & Cell Therapy Coordination Service
Our coordination service for international patients exploring CAR-T in China
Online MDT Second Opinion
Request a structured expert review before any treatment decision
Pediatric Leukemia & Blood Disorders
For families facing pediatric leukemia and complex transplant decisions
Haploidentical Transplant
For patients without a matched donor considering haplo-HSCT
Request a Structured CAR-T Eligibility Review
If you or a family member is facing relapsed or refractory disease and wants to understand whether CAR-T therapy in China may be relevant, a structured second opinion is the appropriate first step.